| 8/28/2009 | SS | Noven shares stop trading following company's acquisition by Hisamitsu
|
| 8/27/2009 | SS | Hisamitsu completes tender, will acquire Noven via short-form merger
|
| 8/20/2009 | SS | Hisamitsu begins subsequent offer for Noven Pharmaceuticals
|
| 8/13/2009 | SS | Noven Pharmaceuticals, Hisamitsu merger one step closer to completion
|
| 7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
| 7/14/2009 | SS | Noven Pharmaceuticals to sell to Hisamitsu for $428 million in cash
|
| 7/14/2009 | SS | Market Commentary: Noven deal may trigger Novartis interest; Exelon likely to bid again; IPC stock spread grows
|
| 11/7/2006 | BT | RBC maintains Noven at $20 price target
|
| 11/7/2006 | BT | Noven gets hold rating from Jefferies
|
| 11/6/2006 | BT | Noven's quarterly revenues up 28%, boosted by Daytrana sales
|
| 10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
| 9/15/2006 | BT | Noven down to hold by Jefferies
|
| 9/12/2006 | BT | RBC holds Noven at sector perform
|
| 8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
| 8/29/2006 | BT | Jefferies updates specialty pharmaceutical market
|
| 8/28/2006 | BT | RBC rates Noven at sector perform
|
| 8/22/2006 | BT | Noven gets sector perform rating from RBC
|
| 8/16/2006 | BT | Noven at sector perform by RBC
|
| 8/10/2006 | BT | Noven maintained at buy by Jefferies
|
| 8/10/2006 | BT | RBC keeps Noven at sector perform
|
| 8/9/2006 | BT | Noven says it may earn $25 million milestone by year end, posts $3.3 million second quarter net income
|
| 8/1/2006 | BT | Jefferies upgrades Noven to buy
|
| 6/28/2006 | BT | Jefferies puts Noven at hold
|
| 6/7/2006 | BT | Noven identifies opportunities for future Dot Matrix collaborations
|
| 5/25/2006 | BT | Shire's attention-deficit drug Daytrana shows shorter wear time
|
| 5/2/2006 | BT | Noven maintains hold rating from Jefferies
|
| 5/2/2006 | BT | Market Commentary: Vical top pick in bird flu flock; Noven sinks on profit taking; NitroMed dives, Myriad higher
|
| 5/1/2006 | BT | Noven first-quarter net revenues decrease 13% to $10.2 million
|
| 5/1/2006 | BT | Noven on hold by Jefferies
|
| 4/25/2006 | BT | Jefferies puts Noven at hold
|
| 4/7/2006 | BT | Noven at hold by Jefferies
|
| 3/10/2006 | BT | Noven's resubmitted Daytrana NDA to be reviewed by April 9
|
| 3/8/2006 | BT | Noven at hold by Jefferies
|
| 12/30/2005 | BT | Noven price target raised by Jefferies
|
| 12/23/2005 | BT | Shire, Noven receives FDA approvable letter for Daytrana ADHD drug
|
| 12/5/2005 | BT | Noven reiterated at hold by Jefferies
|
| 12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
| 12/2/2005 | BT | Shire, Noven says FDA advisory committee gave Daytrana patch for ADHD a thumb's up
|
| 12/1/2005 | BT | Noven downgraded by Jefferies to hold
|
| 11/4/2005 | BT | Jefferies maintains Noven's buy rating
|
| 10/13/2005 | BT | Market Commentary: Human Genome finds volatility players get it; Access Pharma off, then steadies; Endo, Noven firm
|
| 9/29/2005 | BT | Noven price target lowered by Jefferies
|
| 8/18/2005 | BT | Noven Pharmaceuticals rated buy, Jefferies says
|
| 8/5/2005 | BT | Noven maintained by Jefferies at buy
|
